FL
Haematology · 2006–2026
13decisions
4medicines
4carried consumer input
27individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tafasitamab Relapsed or refractory follicular lymphoma in patients who have had at least 1 prior systemic anti-CD20 therapy, treated in combination with lenalidomide and… | Mar 2026 | Recommended with restriction | no section in document |
| tafasitamab Treatment of adults with relapsed or refractory follicular lymphoma who have had at least 1 prior systemic anti-CD20 therapy, in combination with lenalidomide… | Nov 2025 | Deferred | no section in document |
| rituximab CD20 positive, previously untreated, stage III/IV follicular, B-cell non-Hodgkin's lymphoma; and CD20 positive, relapsed or refractory low grade or follicular,… | Mar 2019 | Recommended with restriction | unclear |
| obinutuzumab Previously untreated advanced follicular lymphoma (Stage II bulky or Stage III/IV) and rituximab-refractory follicular lymphoma, in both induction/re-induction… | Mar 2018 | Recommended with restriction | 1 individuals Lymphoma Australia |
| obinutuzumab Previously untreated advanced follicular lymphoma (stage II bulky or stage III/IV, CD20 positive) as first-line induction and maintenance therapy. | Nov 2017 | Not recommended | 2 individuals |
| idelalisib Refractory follicular B-cell non-Hodgkin's lymphoma in patients refractory to both rituximab and an alkylating agent, as monotherapy. | Jul 2016 | Recommended with restriction | input received |
| idelalisib Treatment of relapsed/refractory follicular lymphoma that has progressed despite prior treatment with rituximab and an alkylating agent. | Mar 2016 | Deferred | none received |
| obinutuzumab Treatment of patients with rituximab-refractory follicular lymphoma in combination with bendamustine for induction therapy, followed by obinutuzumab… | Nov 2016 | Not recommended | 24 individuals |
| idelalisib Treatment of adult patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (follicular lymphoma) who have received at least two prior… | Mar 2015 | Not recommended | none received |
| idelalisib Treatment of follicular lymphoma that is refractory to both rituximab and an alkylating agent. | Nov 2015 | Deferred | none received |
| rituximab Maintenance therapy for follicular lymphoma in patients who have achieved a partial or complete response to induction treatment in first-line and… | Jul 2014 | Recommended with restriction | unclear |
| rituximab Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin’s lymphoma, in combination with… | Mar 2006 | Recommended with restriction | no section in document |
| rituximab Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with… | Mar 2006 | Recommended with restriction | no section in document |
Who spoke
Lymphoma Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.